Mounjaro India sales overtake Augmentin as generic semaglutide volumes jump

Mounjaro India sales have carried Eli Lilly's tirzepatide brand to the top of the country's drug sales charts, Mint reported on 4 November. The patented medicine displaced GlaxoSmithKline's antibiotic Augmentin, long the bestseller in a market built on cheap, high volume generics. Generic semaglutide, sold by Indian firms since Novo Nordisk's patent lapsed in March 2026, is growing even faster by units. Together they show Indian patients paying more for newer peptide medicines. Whether those patients stay on treatment for a year or longer is still unknown.

Mounjaro India sales lead a market built on generics

Mounjaro is now India's top selling medicine by value, Mint reports in an analysis built on Pharmarack data. That is a sharp change in a market where most prescriptions are low cost branded generics sold in very large volumes. Lilly launched Mounjaro in India in March 2025. Pharmarack, an e-commerce market audit company, counted ₹923 crore in sales for the brand in the 2025-26 financial year and about ₹1,736 crore in the 12 months to September 2026. A crore is 10 million rupees. Over the same 12 months, Pharmarack put the whole GLP-1 class at ₹2,596 crore, with injectable products making up about 86% of that value. The remainder comes from non-injectable forms such as tablets, a much smaller slice of spending.

By our calculation from the Mounjaro India sales figures, one patented brand took about two thirds of the class's value over the past year, even though the class includes several cheaper rivals. Mint compares the trend to buyers queuing for a new iPhone, with urban patients chasing the newest injection almost regardless of price. Vishal Manchanda, a pharma analyst at Systematix Group, told Mint that the overall GLP-1 market could be close to ₹3,000 crore. He added that India had not yet "scratched the surface" compared with use in the United States. That is his view, not a forecast backed by published data. An ICMR-INDIAB study cited by Mint estimates obesity in India affects about 254 million people and diabetes about 101 million, though not all would be candidates for these drugs.

Generic semaglutide volumes jump sixteen fold

Novo Nordisk's main semaglutide patent in India expired in March 2026, and several Indian drugmakers launched copies soon after. By value, the molecule brought in ₹113 crore in September, more than double its ₹48 crore haul in February 2026, Mint reports. Monthly units rose close to sixteen times, from about 114,000 to 1,876,000, and generics made up nearly 74% of units sold. Value grew far more slowly than volume, which suggests that much of the new demand went to lower priced copies. Even so, Mint puts monthly treatment costs between ₹1,850 and ₹8,000, a large sum for many households in a market used to cheap pills. Manchanda estimates that semaglutide alone is now selling at an annualised rate of about ₹900 crore across the country.

Monthly units rose close to sixteen times, from about 114,000 to 1,876,000, and generics made up nearly 74% of units sold.

The field filled up fast. Diabetologist Rajiv Kovil told Mint, "You have 50 brands which have come out and you have almost eight to nine different kinds of devices." He said the spread of devices confused doctors as well as patients, though some firms have since worked to rebuild physician trust. Alkem Laboratories, one of the March entrants, launched three brands, Semasize, Obesema and Hepaglide, in both prefilled disposable pens and reusable devices. Managing director Sandeep Singh said access depends on ease of use as well as price, and Alkem pairs its products with support groups on diet, exercise and side effects. Rankings among the copies are contested, and Eris Lifesciences says its Sundae brand leads prescriptions and unit sales.

Brand trust and pen design shape patient choice

Mint's reporting suggests that brand reputation often acts as a stand in for efficacy in a class where finding the right dose takes months and responses differ widely. Aakanksha Chauhan, a 37 year old engineer who runs a GLP-1 coaching community, told Mint that members often assume Mounjaro will work better when their progress on a generic slows. "People think it is a superior drug as that is how it has been sold to the market," she said. Mint stresses that such group chats are not clinical evidence. A Delhi patient who tried Sun Pharmaceutical's Noveltreat and Zydus' Semaglyn over four months said he had not felt the appetite effect he expected. Mounjaro was suggested to him, but he has held back because of its cost.

Device design also shapes the choice. Some patients prefer multi use pens because they lower costs over time, while others pick single use pens for convenience or privacy at home, Mint reports. Kovil said the harder test lies beyond price. "In GLP-1, it's always about the durability of the prescription," he told Mint, adding that keeping patients on treatment for a year would be the first hurdle. He expects the class could come to resemble statins, where low prices and wide supply built a large patient base. Manchanda sees a shift toward companies reaching patients directly, with word of mouth and doctors' experience of each product counting for more. Neither view comes with figures on how many Indian patients stop treatment early.

Lilly Cipla and Novo Nordisk bet on a faster India

Multinationals are reading the Mounjaro India sales figures as a signal. Anil Matai, director general of the Organisation of Pharmaceutical Producers of India, told Mint that the delay between global and Indian launches of patented drugs has shrunk from over seven or eight years to two or three. "The success story of GLP-1 drugs greatly reinforces their confidence," he said. Lilly has added reach through a commercial deal with Cipla for Yurpeak, its second tirzepatide brand, which draws on Cipla's distribution network. Lilly says its work also covers raising awareness of obesity as a chronic disease. Roche, outside the peptide field, plans more than 20 launches or new indications in India over three to five years, and in October 2025 pledged at least CHF 1.5 billion in India over five years.

Novo Nordisk, which lost exclusivity on semaglutide in India, stresses physician confidence, affordability, steady supply and its integrated medicine and pen system. Its India managing director, Vikrant Shrotriya, has said that "changing an entrenched perception takes sustained effort", a remark about how obesity is understood. Demand is also spilling into the retatrutide grey market. Retatrutide is an experimental Lilly drug still in Phase 3 trials in the United States, so it is not an approved medicine, yet Mumbai colorectal surgeon Sambit Patnaik told Mint that some of his patients are obtaining it. Unapproved injections carry real risks of fake or contaminated product, and British regulators have seized thousands of fake retatrutide and tirzepatide pens in recent raids. Patients should use licensed medicines only under medical care.

Conclusion

Mounjaro India sales show that a patented peptide brand can lead a market long run on low prices, while generic semaglutide proves that cheaper copies can multiply volumes within months. The open questions are adherence and margins. Kovil's one year retention test, the effect of price competition on generic makers, and the next Pharmarack audits will show whether this spending lasts. Mint's figures come from market audits, not company accounts, and Mint reported no retention data from any maker. This report is for information only and is not medical advice.